Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Matthew P Thorpe

Showing results (31-40 of 38) with videos related to

Pageof 4
Sort By:
You have reached the last page of results.This site can display upto 38 results.
Cancer Treatment Reviews|April 16, 2025
Current and future directions in theranostics for neuroendocrine prostate cancerGokce Belge Bilgin, Fabrice Lucien-Matteoni, Aadel A Chaudhuri, et al.
Blood Cancer Journal|August 17, 2023
Metabolic PET/CT analysis of aggressive Non-Hodgkin lymphoma prior to Axicabtagene Ciloleucel CAR-T infusion: predictors of progressive disease, survival, and toxicityWilliam G Breen, Jason R Young, Matthew A Hathcock, et al.
European Journal of Nuclear Medicine and Molecular Imaging|July 21, 2025
[<sup>177</sup>Lu] Lu-PSMA-617 treatment for metastatic castration-resistant prostate cancer (mCRPC) with cerebral and cerebellar metastasesGokce Belge Bilgin, Cem Bilgin, Brian J Burkett, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|October 30, 2024
Outcomes for Patients with Metastatic Castration-Resistant Prostate Cancer and Liver Metastasis Receiving [<sup>177</sup>Lu]Lu-PSMA-617Miguel Muniz, Oliver Sartor, Jacob J Orme, et al.
European Urology Oncology|August 2, 2025
Outcomes for [<sup>177</sup>Lu]Lu-PSMA-617 with and Without Concurrent Use of Androgen Receptor Pathway Inhibitors in Patients with Metastatic Castration-resistant Prostate CancerMiguel Muniz, Oliver Sartor, Jacob J Orme, et al.
Cancer Treatment Reviews|May 4, 2024
Salivary toxicity from PSMA-targeted radiopharmaceuticals: What we have learned and where we are goingMiguel Muniz, Charles L Loprinzi, Jacob J Orme, et al.
Clinical Genitourinary Cancer|April 17, 2026
LuRa: Efficacy and Safety of Radium-223 Following [<sup>177</sup>Lu]Lu-PSMA-617 in Patients With Metastatic Castration-Resistant Prostate CancerJabra Zarka, Ronit Juthani, Oliver Sartor, et al.
Journal of the American College of Radiology : JACR|August 1, 2021
Factors Influential in the Selection of Radiology Residents in the Post-Step 1 World: A Discrete Choice ExperimentCharles M Maxfield, J Felipe Montano-Campos, Teresa Chapman, et al.
Pageof 4

Showing results (31-40 of 38) with videos related to

Sort By:
Pageof 4
You have reached the last page of results.This site can display upto 38 results.
Cancer Treatment Reviews|April 16, 2025
Current and future directions in theranostics for neuroendocrine prostate cancerGokce Belge Bilgin, Fabrice Lucien-Matteoni, Aadel A Chaudhuri, et al.
Blood Cancer Journal|August 17, 2023
Metabolic PET/CT analysis of aggressive Non-Hodgkin lymphoma prior to Axicabtagene Ciloleucel CAR-T infusion: predictors of progressive disease, survival, and toxicityWilliam G Breen, Jason R Young, Matthew A Hathcock, et al.
European Journal of Nuclear Medicine and Molecular Imaging|July 21, 2025
[<sup>177</sup>Lu] Lu-PSMA-617 treatment for metastatic castration-resistant prostate cancer (mCRPC) with cerebral and cerebellar metastasesGokce Belge Bilgin, Cem Bilgin, Brian J Burkett, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|October 30, 2024
Outcomes for Patients with Metastatic Castration-Resistant Prostate Cancer and Liver Metastasis Receiving [<sup>177</sup>Lu]Lu-PSMA-617Miguel Muniz, Oliver Sartor, Jacob J Orme, et al.
European Urology Oncology|August 2, 2025
Outcomes for [<sup>177</sup>Lu]Lu-PSMA-617 with and Without Concurrent Use of Androgen Receptor Pathway Inhibitors in Patients with Metastatic Castration-resistant Prostate CancerMiguel Muniz, Oliver Sartor, Jacob J Orme, et al.
Cancer Treatment Reviews|May 4, 2024
Salivary toxicity from PSMA-targeted radiopharmaceuticals: What we have learned and where we are goingMiguel Muniz, Charles L Loprinzi, Jacob J Orme, et al.
Clinical Genitourinary Cancer|April 17, 2026
LuRa: Efficacy and Safety of Radium-223 Following [<sup>177</sup>Lu]Lu-PSMA-617 in Patients With Metastatic Castration-Resistant Prostate CancerJabra Zarka, Ronit Juthani, Oliver Sartor, et al.
Journal of the American College of Radiology : JACR|August 1, 2021
Factors Influential in the Selection of Radiology Residents in the Post-Step 1 World: A Discrete Choice ExperimentCharles M Maxfield, J Felipe Montano-Campos, Teresa Chapman, et al.
Pageof 4